MBRX

Moleculin Biotech Inc

8.60

Nov 09 • 2:33 PM ET -0.10 (-1.16%)

Healthcare Biotechnology USA Nano NASD

Peers: CNSP ATNM GTBP KURA SNTI SNDX JAZZ RIGL CLRB KPTI

Index	-
Market Cap	9.02M
Enterprise Value	2.05M
Income	-32.52M
Sales	0.00M
Book/sh	32.64
Cash/sh	6.92
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Jun 02, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.26
P/C	1.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.94
Current Ratio	0.94
Debt/Eq	0.03
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-342.74
EPS next Y	-23.40
EPS next Q	-8.87
EPS this Y	88.51%
EPS next Y	64.18%
EPS next 5Y	64.05%
EPS past 3/5Y	57.89% 46.71%
Sales past 3/5Y	- -
EPS Y/Y TTM	85.06%
Sales Y/Y TTM	-
EPS Q/Q	88.60%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	9.87% -

Insider Own	10.67%
Insider Trans	0.00%
Inst Own	7.81%
Inst Trans	-
ROA	-142.11%
ROE	-1371.64%
ROIC	-258.45%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.45%
SMA50	-17.03%
SMA200	-77.34%
Trades

Shs Outstand	1.05M
Shs Float	0.94M
Short Float	0.67%
Short Ratio	0.13
Short Interest	0.01M
52W High	253.05 -96.60%
52W Low	3.23 166.40%
Volatility	7.98% 13.94%
ATR (14)	1.02
RSI (14)	48.70
Beta	2.02
Rel Volume	0.32
Avg Volume	47.46K
Volume	12,006

Perf Week	3.36%
Perf Month	-2.72%
Perf Quarter	-3.38%
Perf Half Y	-82.38%
Perf YTD	-87.01%
Perf Year	-96.48%
Perf 3Y	-99.79%
Perf 5Y	-99.95%
Perf 10Y	-99.99%
Recom	1.00
Target Price	240.00
Prev Close	8.70
Price	8.60
Change %	-1.16%

Consensus

Strong Buy

Avg. Price Target

$240.00

Implied Upside

+2,690.9%

Analysts3incl. previous ratings

Rating Distribution2 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 09, 2025	Resumed	HH.C. Wainwright	Buy	$4	-53.5%
Feb 12, 2025	Downgrade	MMaxim Group	Buy → Hold
Jul 18, 2022	Resumed	OOppenheimer	Outperform	$14	+62.8%

Nov-04-26 11:00AM	Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-30-26 08:40AM	Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 (GlobeNewswire) -9.40%
Oct-20-26 08:12AM	Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial (GlobeNewswire) +16.79%
Oct-16-26 09:20AM	Moleculin Announces Reverse Stock Split (GlobeNewswire) -24.24%
Oct-07-26 08:45AM	Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit (GlobeNewswire)
08:45AM	Loading…
Sep-29-26 08:45AM	Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout (GlobeNewswire) -7.49%
Sep-28-26 07:00AM	Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine (GlobeNewswire) -5.42%
Sep-25-26 01:05PM	Annamycin Turns "Cold" Pancreatic Tumors "Hot" in New Preclinical Data Presented at AACR (GlobeNewswire) +6.12%
Sep-23-26 08:25AM	Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 (GlobeNewswire) -6.57%
Sep-14-26 08:35AM	Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings (GlobeNewswire) +8.42%
Sep-11-26 08:30AM	Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand (GlobeNewswire) -13.85%
Aug-27-26 09:01AM	Moleculin CEO, Walter Klemp, Participates in the Virtual Investor "Why Now" On-Demand Conference (GlobeNewswire) +14.78%
Aug-14-26 08:30AM	Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial (GlobeNewswire) +7.16%
Jul-31-26 10:12AM	Moleculin Announces Pricing of $9.3 Million Public Offering (GlobeNewswire) -60.78%
08:10AM	Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients (GlobeNewswire)
08:33AM	Loading…
Jul-06-26 08:33AM	Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment (GlobeNewswire) -9.09%
Jun-30-26 02:52PM	MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance (Stocktwits) -21.85%
08:30AM	Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control (GlobeNewswire)
Jun-05-26 08:29AM	Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML (GlobeNewswire)
Jun-04-26 08:31AM	Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" Segment (GlobeNewswire)
May-29-26 08:21AM	Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits (GlobeNewswire)
May-21-26 05:02PM	Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin (GlobeNewswire)
May-15-26 08:30AM	Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial (GlobeNewswire)
May-13-26 08:00AM	Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks (GlobeNewswire) -8.55%
May-12-26 09:30AM	Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits (GlobeNewswire)
May-08-26 08:45AM	Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin (GlobeNewswire)
Apr-23-26 08:25AM	Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 (GlobeNewswire)
Apr-21-26 08:36AM	Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting (GlobeNewswire)
Apr-07-26 08:36AM	Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile (GlobeNewswire)
Mar-27-26 09:15AM	Scalable Biotech Manufacturing Unlocks a $14B Market (PR Newswire)
08:31AM	Loading…
Mar-23-26 08:31AM	Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout (GlobeNewswire)
Mar-19-26 08:36AM	Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 (GlobeNewswire)
Mar-17-26 09:05AM	Moleculin to Present at 38th Annual ROTH Conference (GlobeNewswire) +5.37%
Mar-11-26 09:00AM	Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study (GlobeNewswire)
Feb-19-26 08:39AM	Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds (GlobeNewswire) -44.28%
Feb-18-26 08:20AM	Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) (GlobeNewswire) +5.48%
Feb-17-26 08:35AM	Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin (GlobeNewswire) +5.07%
Feb-13-26 08:32AM	Moleculin Launches CEO Corner Platform to Share Strategic Insights (GlobeNewswire)
Feb-05-26 09:15AM	Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire) -6.46%
Jan-13-26 08:55AM	Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects (GlobeNewswire) +5.93%
Jan-12-26 08:36AM	Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs (GlobeNewswire)
Dec-17-25 08:31AM	Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors (GlobeNewswire) -11.73%
Dec-10-25 08:30AM	Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds (GlobeNewswire) -27.15%
Dec-09-25 08:07AM	Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026 (GlobeNewswire) -8.55%
Dec-08-25 08:21AM	Moleculin Announces New Annamycin Collaboration in Brain Tumors (GlobeNewswire)
Nov-26-25 09:15AM	Moleculin to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -22.03%
09:00AM	Moleculin Announces Reverse Stock Split (GlobeNewswire)
Nov-13-25 08:36AM	Moleculin Reports 60% of First 45 Subjects in Pivotal "MIRACLE" Phase 3 AML Trial Consented (GlobeNewswire) -6.91%
Nov-12-25 08:37AM	Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill (GlobeNewswire)
Oct-30-25 08:40AM	Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting (GlobeNewswire) -5.80%
Oct-29-25 08:35AM	Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin (GlobeNewswire)
Oct-23-25 08:00AM	Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer (GlobeNewswire) +9.81%
Oct-21-25 09:20AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Sep-26-25 08:45AM	Moleculin Biotech announces issuance of Canadian patent covering Annamycin (TipRanks) +11.87%
Sep-25-25 08:35AM	Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin (GlobeNewswire)
Sep-17-25 12:00PM	Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know (Zacks) +5.18%
Sep-09-25 08:45AM	Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial (GlobeNewswire)
Sep-08-25 08:30AM	Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia (GlobeNewswire)
Aug-28-25 08:30AM	Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds (GlobeNewswire) -35.27%
Aug-27-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +11.33%
08:45AM	Moleculin Issues New Positive AML Overall Survival Data: (GlobeNewswire)
Aug-14-25 09:15AM	Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Aug-13-25 08:05AM	Moleculin Reports Second Quarter 2025 Financial Results and Highlights (GlobeNewswire)
Aug-06-25 08:40AM	Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment (GlobeNewswire)
Jul-30-25 08:35AM	Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin (GlobeNewswire)
Jul-22-25 08:45AM	Moleculin Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-17-25 08:25AM	Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships (GlobeNewswire) +30.56%
Jul-09-25 08:35AM	Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans (GlobeNewswire) +9.70%
Jun-21-25 09:25AM	Moleculin Biotech prices 16.08M shares at 37c in public offering (TipRanks)
Jun-20-25 09:20AM	Moleculin Announces $5.9 Million Public Offering (GlobeNewswire) -54.20%
Jun-18-25 07:45AM	Moleculin Participates in Virtual Investor "What This Means" Segment (GlobeNewswire) -12.46%
07:30AM	Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML (GlobeNewswire)
Jun-12-25 09:20AM	Moleculin Biotech announces What This Means virtual investor segment (TipRanks)
Jun-11-25 09:15AM	Moleculin Participates in Virtual Investor "What This Means" Segment (GlobeNewswire)
Jun-05-25 08:00AM	Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107) (GlobeNewswire)
Jun-04-25 08:45AM	Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) (GlobeNewswire) -19.83%
May-15-25 03:12AM	Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com) -8.17%
May-14-25 07:30AM	Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -7.20%
May-13-25 05:19AM	EMA approves Moleculins application for Phase IIb/III AML trial (Clinical Trials Arena)
May-12-25 08:40AM	Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial (GlobeNewswire)
May-07-25 09:00AM	Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast (GlobeNewswire)
May-06-25 09:00AM	Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin (GlobeNewswire)
May-05-25 08:45AM	Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents (GlobeNewswire)
Apr-29-25 08:35AM	Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer (GlobeNewswire)
Apr-17-25 08:30AM	Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-02-25 08:41AM	Moleculin Biotech doses first patient in Phase 3 MIRACLE trial (TipRanks)
05:51AM	Moleculin Biotech begins dosing subjects in combination therapy trial for AML (Clinical Trials Arena)
Apr-01-25 09:55AM	Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
08:30AM	Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial (GlobeNewswire)
Mar-26-25 12:00PM	All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy (Zacks) -6.96%
Mar-25-25 03:00AM	Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com) +8.49%
01:38AM	Q4 2024 Moleculin Biotech Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-24-25 10:50AM	Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:05AM	Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-25 08:05AM	Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast (GlobeNewswire)
Mar-11-25 08:45AM	Moleculin Biotech, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (PR Newswire)
Mar-10-25 08:45AM	Moleculin to Present at the 37th Annual ROTH Conference (PR Newswire)
Mar-06-25 08:30AM	Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity (PR Newswire) -5.17%
Mar-03-25 08:30AM	Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium (PR Newswire) -10.85%

Show Previous News

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.

ChairmanMr. Walter V. Klemp

Executive VP & CFOMr. Jonathan P. Foster CPA

Chief Scientific OfficerDr. Donald H. Picker Ph.D.

Co-FounderDr. Waldemar Priebe Ph.D.

Sc.D.Dr. John Paul Waymack M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MBRX

Moleculin Biotech Inc

Upgrade your Finviz experience